Collaborative Strategies for the Interprofessional Team: Advancing Clinical Outcomes in CLL Using Novel Agents
This educational initiative is targeted to hematologists/oncologists, oncology specialists, pharmacists, nurse practitioners, nurses, and other members of the oncology care team who treat patients with chronic lymphocytic leukemia (CLL).
- Examine relevant prognostic factors in chronic lymphocytic leukemia (CLL) and assess the importance of molecular testing to guide clinical decision making and treatment selection.
- Appraise the latest trial data and practice guidelines for the use of novel, targeted agents in CLL and analyze strategies to optimize therapy selection based on clinical factors and patient preferences.
- Explore key clinical pearls and differentiating factors between novel, targeted therapies in CLL, and discuss practical solutions and innovations to mitigate factors that may complicate the use of the most clinically appropriate therapy.
- Appraise interprofessional strategies to optimize testing, treatment selection, management, and continuum of care for CLL patients and strategies to increase collaboration with the team including specialists (e.g., cardiology) and oncology clinicians of various practice settings.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from AstraZeneca.
5 min Welcome and Introductions/Pre-test
10 min Reviewing Relevant Prognostic Factors in CLL: The Importance of Classification in Disease Management
15 min Exploring Best Practices in the Treatment of CLL: Novel Agents at the Forefront
25 min Optimizing CLL Patient Outcomes in Practice: Multidisciplinary Strategies for the Oncology Care Team
5 min Conversations with the Experts and Q&A/Post-test
John N. Allan, MD
Weill Cornell Medicine
New York, NY
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Sandra E. Kurtin, PhD, ANP-C, AOCN–has disclosed that she is an advisor or consultant to Abbvie, Amgen, AstraZeneca, BMS, GSK, and lncyte.
Jennifer A. Woyach, MD–has disclosed that she receives research support from Janssen, Karyopharm Therapeutics, MorphoSys, Pharmacyclics, and Schrodinger. She is also an advisor or consultant to Abbvie, AstraZeneca, Beigene, Genetech, Janssen, Loxo Oncology, Inc., Newave, and Pharmacyclics.
Lauren Willis, PharmD, BCOP–has no relevant financial relationships to disclose in relation to the content of this activity.
John N. Allan, MD–has disclosed that he receives research support from BeiGene, Celgene, Genentech, Janssen, and TG Therapeutics. He is on the speakers bureau for Abbvie, BeiGene, Janssen, and Pharmacyclics. He is also an advisor or consultant to Abbvie, Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, BeiGene, Epizyme, Genentech, Janssen, Lilly, Pharmacyclics, and TG Therapeutics.
Katherine Lee, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Susan H. Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1 hour of Interprofessional Continuing Education (IPCE) credit for learning and change.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-22-012-L01-P)
This activity is designated for 1.0 contact hour.
Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 IPCE
- 1.00 Participation